FSD Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cobourg ON Canada (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2020
NCT04619706
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

FSD Pharma | FSD Pharma, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: FSD Pharma (0) Acquired (1)

mupirocin (bactroban) (1 trial)

Drugs in Phase 3 Trials (1)

Key: FSD Pharma (0) Acquired (1)

palmitoylethanolamide (5 trials)

Drugs in Phase 2 Trials (7)

Key: FSD Pharma (0) Acquired (7)

chlorhexidine (hibitane) (1 trial)

dronabinol (marinol) (2 trials)

Exeporfinium (2 trials)

inactivated influenza vaccine (1 trial)

muromonab cd3 (Orthoclone OKT3) (1 trial)

sodium chloride (1 trial)

teplizumab (Tzield) (1 trial)

Drugs in Phase 1 Trials (1)

lucid-21-302 (1 trial)

Indications

Overview

  • Highest Phase: Phase 1
  • # of Trials: 12
  • # of Trial APIs: 10